Group
Biotech
11 themes97 tickers
10D rank10D#160of 172 groups/172
Dive into Biotech, where we explore everything from established pharma giants and cutting-edge GLP-1 therapies to revolutionary oncology, genetic medicine, and AI-driven drug discovery. Understand what's going on in health innovation!
GLP1+5.48%9.1%
Oncology+26.94%9.1%
Pharma/Therapeutics+10.96%9.1%
Commercial / Late Stage+0.54%9.1%
Neurology, CNS & Rare Disorders+18.17%9.1%
Oncology & Immunotherapy+75.32%9.1%
RNA-Based/Genetic Medicine+82.71%9.1%
AI Driven Drug Discovery+89.15%9.1%
Established Pharma+25.58%9.1%
Psychedelic Drugs+47.97%9.1%
Scalable Oncology Drugs+22.13%9.1%
As of Oct 4, 2026, 4:13 AM ET
Themes in this group
| Biotech '24: OncologyOncology | 8 | $4.17B | $33.36B | -0.02% | +1.22% | -2.09% | +0.72% | +43.81% | +26.94% | +75.66% | -9.68% | +21.46% | +26.15% | +25.10% | +104.83% | +10.12% | +34.91% |
| Biotech '26: AI Driven Drug DiscoveryAI Driven Drug Discovery | 18 | $88.73B | $1.60T | +1.71% | +0.23% | +11.00% | +0.99% | +79.67% | +89.15% | +113.30% | +61.27% | +25.77% | +41.78% | +68.14% | +135.22% | +5.45% | +3.33% |
| Biotech '25: Neurology, CNS & Rare DisordersNeurology, CNS & Rare Disorders | 7 | $1.27B | $8.89B | -0.45% | -2.68% | -3.87% | +0.06% | +6.07% | +18.17% | +46.96% | +253.28% | -1.89% | +3.15% | +1.76% | +90.58% | -2.76% | -0.39% |
| Biotech '25: Commercial / Late StageCommercial / Late Stage | 5 | $5.39B | $26.93B | +0.20% | -3.66% | -6.66% | +0.71% | -13.54% | +0.54% | +22.40% | +83.80% | -1.78% | -3.28% | -6.56% | +16.89% | +10.49% | -2.11% |
| Biotech '26: Established PharmaEstablished Pharma | 10 | $192.11B | $1.92T | +0.06% | -3.68% | -8.17% | +0.29% | +13.14% | +25.58% | +23.98% | +63.80% | +2.01% | +14.16% | +6.00% | +36.17% | +2.99% | +3.56% |
| Biotech '26: Scalable Oncology DrugsScalable Oncology Drugs | 12 | $18.29B | $219.44B | -1.09% | -4.43% | -18.56% | +0.90% | +0.49% | +22.13% | +30.00% | +76.80% | -6.39% | -4.34% | +1.65% | +52.48% | +3.31% | -2.33% |
| Biotech '25: Oncology & ImmunotherapyOncology & Immunotherapy | 12 | $6.15B | $73.85B | -0.55% | -6.04% | -9.41% | +0.22% | +28.55% | +75.32% | +87.99% | +168.69% | +6.11% | +17.29% | +26.19% | +123.74% | +2.97% | +2.41% |
| Biotech '25: RNA-Based/Genetic MedicineRNA-Based/Genetic Medicine | 7 | $4.63B | $32.39B | -1.53% | -7.67% | -17.12% | -0.84% | +47.12% | +82.71% | +66.84% | +104.71% | -2.08% | +18.23% | +31.40% | +268.05% | +3.07% | +16.82% |
| Biotech '24: Pharma/TherapeuticsPharma/Therapeutics | 13 | $3.70B | $48.11B | -0.36% | -9.54% | -12.58% | +0.46% | -1.68% | +10.96% | +29.83% | +111.14% | -3.58% | +6.14% | -3.92% | +64.51% | +10.62% | -4.95% |
| Biotech '24: GLP1GLP1 | 4 | $8.19B | $32.78B | +0.99% | -10.57% | -9.59% | +1.00% | -11.92% | +5.48% | -3.03% | +406.32% | -8.00% | -2.25% | -7.36% | +37.51% | +3.53% | -4.59% |
| Biotech '26: Psychedelic DrugsPsychedelic Drugs | 11 | $814.3M | $8.96B | -0.21% | -12.26% | -6.64% | -0.72% | +65.82% | +47.97% | +77.10% | -19.29% | +7.83% | +29.89% | +63.29% | +115.70% | +5.94% | -17.49% |
Default: 10D ↓ · Click headers to sort · Shift+click secondary